Consensus Altimmune, Inc.

Stocks

ALT

US02155H2004

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 11:48:18 2026-07-24 EDT			5-day change	1st Jan Change
2.795 ^USD	-1.58%		-2.96%	-22.85%

07-21	Certain Pre-Funded Warrants of Altimmune, Inc. are subject to a Lock-Up Agreement Ending on 22-JUL-2026.	CI
07-21	Certain Restricted Stock Units of Altimmune, Inc. are subject to a Lock-Up Agreement Ending on 22-JUL-2026.	CI

Evolution of the Average Target: Altimmune, Inc.

Evolution of the Target Price: Altimmune, Inc.

Changes in Analyst Recommendations: Altimmune, Inc.

1f1ce42c3a2e3073cf9cdcd0fed.mrgt5LHo7Tee9fiRX4lDWBzBtmpgPWQRXAGSXfbARgM.09MclN2J323yx4yiL_8bNUz5gAZWdTZ2GmL4NcbwJFbP3nyjx4GCee6AsQ~9049f6dd3356158f4a6dfb543ac1ceda

Analysts' recommendations: Altimmune, Inc.

06-22	Leerink Partners Initiates Altimmune at Outperform With $10 Price Target	MT
04-24	Goldman Sachs Upgrades Altimmune to Neutral From Sell, Adjusts Price Target to $2.50 From $1	MT
03-19	Truist Initiates Altimmune at Buy With $12 Price Target	MT
03-06	B. Riley Adjusts Price Target on Altimmune to $13 From $18, Maintains Buy Rating	MT
01-28	Barclays Initiates Coverage on Altimmune With Overweight Rating, $20 Price Target	MT
25-08-13	UBS Adjusts Price Target on Altimmune to $24 From $26, Maintains Buy Rating	MT
25-08-13	B. Riley Adjusts Price Target on Altimmune to $18 From $20, Maintains Buy Rating	MT
25-02-28	William Blair Initiates Altimmune at Market Perform	MT
25-01-08	Stifel Initiates Altimmune at Buy With $18 Price Target	MT
24-11-12	UBS Initiates Altimmune at Buy With $26 Price Target	MT
24-04-29	Altimmune Shares Decline After Guggenheim Downgrade	MT
24-04-29	Guggenheim Downgrades Altimmune to Neutral From Buy	MT
24-01-17	B. Riley Raises Altimmune's PT to $20 From $15 on Increased Obesity+NASH Therapeutics' Product Sales Projections; Keeps Buy Rating	MT
23-11-09	B. Riley Lowers Altimmune's PT to 8 From $15, Says Updated Model Adjusts for Ongoing Obesity+NASH Market Dynamics; Maintains Buy Rating	MT
23-08-14	HC Wainwright Adjusts Price Target on Altimmune to $15 From $50, Maintains Buy Rating	MT
23-08-11	B. Riley Lowers Altimmune's Price Target to $15 From $20, Keeps Buy Rating	MT
23-08-10	B. Riley Lowers Altimmune's Price Target to $20 From $26, Keeps Buy Rating	MT
23-03-22	Goldman Sachs Downgrades Altimmune to Neutral From Buy, Adjusts Price Target to $6 From $20	MT
23-01-20	HC Wainwright Reiterates Altimmune at Buy With $50 Price Target	MT
23-01-18	Evercore ISI Adjusts Altimmune Price Target to $25 From $14, Maintains Outperform Rating	MT
22-12-01	Goldman Sachs Initiates Altimmune at Buy With $20 Price Target	MT
22-11-11	JMP Securities Adjusts Price Target on Altimmune to $26 From $28, Maintains Market Outperform Rating	MT
22-09-28	Altimmune, Inc. Announces First Dosing of All Subjects in Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight	CI
22-09-16	Guggenheim Adjusts Altimmune's Price Target to $26 From $31, Reiterates Buy Rating	MT
22-08-31	Jefferies Adjusts Altimmune's Price Target to $35 From $30, Reiterates Buy Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ALTIMMUNE, INC.					+494.68%
	WUXI APPTEC CO., LTD.					+18.07%
	ARGENX SE					+11.05%
	BIONTECH SE					+31.98%
	INSMED INCORPORATED					+82.65%
	WUXI BIOLOGICS (CAYMAN) INC.					+19.98%
	GENMAB A/S					+25.63%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+7.98%
	PHARMAESSENTIA CORPORATION					-6.67%
	EXELIXIS, INC.					-6.44%
	Average					+67.89%
	Weighted average by Cap.					+22.20%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.840USD

Average target price

16.89USD

Spread / Average Target

+494.68%

High Price Target

28.00USD

Spread / Highest target

+885.92%

Low Price Target

10.00USD

Spread / Lowest Target

+252.11%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Leerink Partners
Goldman Sachs
Truist Securities
B. Riley
Barclays
UBS
William Blair & Co.
Stifel Nicolaus
Guggenheim
HC Wainwright
Evercore ISI
JMP Securities
Jefferies & Co.
Piper Sandler